NCT06801834 2026-03-19
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
Clinical Trials
12 trialsNCT07099898 2026-03-06
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT07189455 2026-01-05
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Recruiting
NCT05874401 2025-09-04
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Pharmacosmos A/S
Phase 4 Recruiting
NCT06954246 2025-06-18
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06616532 2024-12-19
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Biotheus Inc.
Phase 3 Recruiting
NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
NCT06498479 2024-10-16
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT06128837 2024-03-15
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Luye Pharma Group Ltd.
Phase 3 Recruiting